A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy.

Cancer Manag Res · 2021 · PMC8434866 · PMID 34522140

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

30 , 31 The number of MDSCs, another important immunosuppressive myeloid-derived population, including Ly6C + CD11b + (mMDSCs) and Ly6G + CD11b + (gMDSCs) of mice treated with anti-CLDN18.2-anti-CD28 showed a trend of reduction ( Figure 5B and C ) on day 4 after treatment.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.